Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric carboxymaltose versus iron sucrose in haemodialysis patients with iron deficiency
ACTRN12614000548639Phase 4Completed
- Sponsor
- Eastern Health Integrated Renal Service
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in iron deficiency anemia (IDA) and chronic kidney disease (CKD) comparing Ferric carboxymaltose with Iron sucrose (2 arms). Primary endpoint: Change from baseline to peak intact FGF23 serum concentration. Started Apr 2014; status: completed.
02
Drugs
ferric carboxymaltoseiron sucrose
03
Conditions
iron deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12614000548639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000548639.